HCPCS Level II code A9800 denotes a 1 millicurie dose of Gallium ga-68 gozetotide (locametz), a PET radiopharmaceutical used for diagnostic molecular imaging. This code captures a specific diagnostic agent increasingly used in oncologic imaging to localize disease and guide clinical decision-making. Standardized coding for novel radiopharmaceuticals matters nationally as it affects coverage determinations, billing consistency, and access to advanced imaging.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of payer coverage patterns, national reimbursement benchmarks where available, and the clinical context for using this agent in PET imaging workflows. The publication outlines common billing considerations, coding adjacencies, and service-line placement for imaging departments.

The content provides practical reference material: definition and intended use of the code, typical sites of service, payer landscape, and the types of benchmarks and policy updates readers can expect to consult when evaluating adoption and billing for this diagnostic radiopharmaceutical. Data not available in the input is explicitly noted where relevant.